ArticleCancer chemotherapy and pharmacology2026
Population pharmacokinetics of encorafenib and binimetinib in real-world patients with BRAF
Article in Cancer chemotherapy and pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEncorafenib and binimetinib pharmacokinetic (PK) studies in real-world cancer patients remain scarce. We aimed to characterize their population pharmacokinetics (popPK) in routine clinical care and compare real-life exposure metrics with clinical trials data.
methodsWe conducted population pharmacokinetic (popPK) analyses in real-world patients with BRAFV600E/K-mutant metastatic melanoma to characterize interindividual variability (IIV) and identify significant covariates in MonolixSuite™. Final model-based Bayesian individual PK metrics (i.e., trough concentration, Cmin, maximal concentration, Cmax, unbound average concentration, Caverage, and area under the curve, AUCτ) were compared with data from clinical trials and potency-anchored metrics (reported half-maximal inhibitory concentration, IC50).
resultsData from 66 encorafenib and 69 binimetinib patients (310 and 311 samples) were analyzed. For both drugs, a two-compartment model with first-order absorption and linear elimination best described the data. None of the studied covariates were significantly associated with model parameters. Model-predicted PK metrics (geometric mean and CV(%)) for encorafenib and binimetinib at 450 mg QD and 45 mg BID were: Cmin 19 ng/mL (73%) and 55 ng/mL (56%), Cmax 3378 ng/mL (30%) and 367 ng/mL (24%), and half-lives 12.5 h (95%) and 7.3 h (67%), respectively. Encorafenib AUC24h was 15,785 ng·h/mL (17%) and binimetinib AUC12h was 2003 ng·h/mL (22%). Monte Carlo simulation showed that reducing encorafenib from 450 mg to 300 mg once daily lowered unbound Caverage by 33% while maintaining substantial coverage relative to IC50.
conclusionOverall, these metrics are comparable to those reported in clinical trial data. This population PK model could be useful to explore the exposure-response relationship in future PK/PD studies.
Indexed as
Identifiers
41843134What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.